Merck & Co., Inc.: directors' dealings · United States · SEC (Form 4)

About Merck & Co., Inc.

Merck & Co., Inc. is a leading U.S. pharmaceutical company listed on the NYSE under the ticker MRK and headquartered in Rahway, New Jersey, in the United States. For French-speaking investors, Merck is best understood as a global healthcare platform rather than a single-product story: it operates across prescription medicines, vaccines, biologic therapies, and Animal Health. Outside the United States and Canada, the company uses the MSD brand. Merck reported approximately 75,000 employees and $65.0 billion in 2025 revenue, underscoring its scale as one of the major defensive large-cap names in global healthcare. ([merck.com](https://www.merck.com/media/company-fact-sheet/)) Founded in 1891, Merck has built a long-standing position in global pharmaceuticals through a combination of scientific depth, commercial execution, and sustained R&D investment. Its operating structure is centered on three main businesses: Pharmaceuticals, Vaccines, and Animal Health. The company’s research and development spend reached $15.8 billion in 2025, which reflects the capital intensity of maintaining a pipeline in oncology, infectious diseases, cardiometabolic care, and other therapeutic areas. ([merck.com](https://www.merck.com/media/company-fact-sheet/)) From a competitive standpoint, Merck is particularly strong in oncology and infectious disease prevention, while also holding a meaningful position in animal health. Its best-known franchise remains KEYTRUDA, the immuno-oncology cornerstone that continues to anchor the company’s earnings power. The company has also highlighted the launch momentum of WINREVAIR and the resilience of its Animal Health business as important contributors to 2024 growth. This mix gives Merck both earnings quality and pipeline optionality, although future performance remains highly dependent on patent cycles, clinical success, and launch execution. ([merck.com](https://www.merck.com/stories/our-q4-and-full-year-2024-financial-results/)) Merck’s geographic footprint is broad and diversified. In 2025, the United States generated $36.5 billion of revenue, followed by Europe, the Middle East and Africa at $14.6 billion, Latin America at $3.4 billion, Asia Pacific ex-Japan/China at $3.0 billion, Japan at $2.7 billion, China at $1.9 billion, and Other at $2.9 billion. That distribution shows a company with strong domestic exposure but also meaningful international monetization. ([merck.com](https://www.merck.com/media/company-fact-sheet/)) Recent developments have reinforced the investment case around innovation-led growth. In June 2025, the FDA approved ENFLONSIA, Merck’s RSV preventive monoclonal antibody for newborns and infants entering their first RSV season, adding a new respiratory asset to the portfolio. The company also reported positive Phase 3 data for enlicitide decanoate, an oral PCSK9 inhibitor in hyperlipidemia, and announced an agreement to acquire Cidara Therapeutics for about $9.2 billion to diversify further into late-phase antiviral assets. Taken together, these moves suggest Merck is actively refreshing its growth pipeline while defending its core franchises on the NYSE in the United States. ([merck.com](https://www.merck.com/news/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir/))